[1] Niwa T. Mass spectrometry in the search for uremic toxins [J]. Mass Spectrom Rev, 1997, 16(6): 307-332. [2] Bar-Or D, Rael LT, Bar-Or R, et al. Mass spectrometry analysis of urine and catheter of a patient with purple urinary bag syndrome [J]. Clin Chim Acta, 2007, 378(1/2): 216-218. [3] Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis [J]. J Lab Clin Med, 1994, 124(1): 96-104. [4] Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta1 and progression of renal failure [J]. Kidney Int Suppl, 1997, 63: S211-214. [5] Yamamoto H, Tsuruoka S, Ioka T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells [J]. Kidney Int, 2006, 69(10): 1780-1785. [6] Brunet P, Dou L, Cerini C, et al. Protein-bound uremic retention solutes [J]. Adv Ren Replace Ther, 2003, 10(4): 310-320. [7] de Loor H, Meijers BK, Meyer TW, et al. Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography [J]. J Chromatogr A, 2009, 1216(22): 4684-4688. [8] Hou YC, Tsai SY, Chan SL, et al. Indoxyl sulfate, a uremic toxin, is biotransformed from indoxyl-beta-D-glucoside (indican) in rats [J]. Toxicon, 2008, 52(3): 440-444. [9] Niwa T, Takeda N, Tatematsu A, et al. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography [J]. Clin Chem, 1988, 34(11): 2264-2267. [10] 赵荣伟,俞佳. HPLC荧光检测法测定人血浆中缬沙坦的浓度[J]. 中国临床药理学与治疗学,2005, 10(9): 1038-1040. [11] 初启江. 不同透析方法对硫酸吲哚酚清除效果及其透析后体内变化研究[J].中国老年学杂志,2009, 29(23): 3118-3119. |